If we will provide a better understanding of underlying mechanisms of myelomagenesis, then we will be able to reach are goals to (1) define high-risk precursor disease patinets, and to (2) delay and prevent development of multiple myeloma. For example, in 2010, we opened a treatment study for smoldering, using a novel treatment approach modality (a monoclonal antibody which targets natural killer cells, which in turn will cause anti-myeloma effect). In 2011, we have developed the second generation of treatment studies based on our generated data from the molecular profiling studies we are doing in parallel. If we will be able to goals to delay/prevent myeloma, it will have a major impact on the clinical management and outcome for these patients in the future.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Shebl, Fatma M; Yu, Kai; Landgren, Ola et al. (2012) Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses 28:809-15
Ludwig, Heinz; Durie, Brian G M; McCarthy, Philip et al. (2012) IMWG consensus on maintenance therapy in multiple myeloma. Blood 119:3003-15
Kumar, S K; Lee, J H; Lahuerta, J J et al. (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26:149-57
Kristinsson, Sigurdur Yngvi; Landgren, Ola (2012) Thromboprophylaxis in multiple myeloma: is the evidence there? Expert Rev Anticancer Ther 12:291-4
Thomas, Anish; Mailankody, Sham; Korde, Neha et al. (2012) Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 119:2731-7
Landgren, O; Ma, W; Kyle, R A et al. (2012) Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia 26:844-5
Liden, Y; Olofsson, N; Landgren, O et al. (2012) Pain and anxiety during bone marrow aspiration/biopsy: Comparison of ratings among patients versus health-care professionals. Eur J Oncol Nurs 16:323-9
Kwok, Mary; Korde, Neha; Landgren, Ola (2012) Bortezomib to treat the TEMPI syndrome. N Engl J Med 366:1843-5
Tembhare, Prashant; Yuan, Constance; Korde, Neha et al. (2012) Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leuk Lymphoma 53:721-4
Engels, E A; Preiksaitis, J; Zingone, A et al. (2012) Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. Am J Transplant 12:1268-74

Showing the most recent 10 out of 36 publications